Avia Pharma acquires two skin products from Perrigo

On December 31, 2019, Avia Pharma acquired the rights to ACO Karbamid and ACO Glycerol from Perrigo.

-We are particularly pleased to be the owner of two high quality Perrigo products. The acquisition is fully in line with our goal of owning products both within self-care products as well as within prescription drugs, says Jacob Calmvik, CEO of Avia Pharma.

ACO Karbamid and ACO Glycerol will be renamed Curemid and Cremarol in the fall of 2020. The products are now registered only in Sweden, but are expected to be registered in additional countries.

Ämnen

Hälsa, sjukvård, läkemedel

Kontakter

Jacob Calmvik

Presskontakt VD Affärsutveckling, förvärv, bolagsövergripande frågor jacob.calmvik@aviapharma.se 070-3707169

Marie Wikman

Presskontakt Nordisk affärsområdeschef OTC, medicinteknik, kosttillskott marie.wikman@aviapharma.se 0708168816

Mattias Wik

Presskontakt Nordisk affärsområdeschef RX mattias.wik@aviapharma.se +46 706 657675

Relaterat innehåll

24 September 2020 12:24

Region Skåne väljer palmoljefri D-vitamin

Eftersom D-vitamin tillhör en av de få vitaminer man kan få i sig för lite av rekommenderas alla barn från 1 veckas ålder upp till 2 år tillskott dagligen av D-vitamindroppar. D-vitamindroppar delas ut gratis av BVC. Det ser olika ut i landet när det gäller vilken D-vitamin som föräldrar får på BVC.
-Glädjande besked är att region Skåne förlänger vårt avtal och därmed ger sin regions nyfödda A

6 Maj 2020 14:50

Örebro, Värmland och Södermanland väljer palmoljefri D-vitamin

Örebro, Värmland och Södermanland nu väljer att ge sina regioners nyfödda ACO D-vitamin med solrosolja, istället för en D-vitamin som innehåller palmolja.

Avia is a leading Swedish OTC/Rx distribution company with presence in the Nordics and Germany.

We work in the most important field there is – health. Health is fundamental in order to experience and enjoy all aspects of life. It is with this strong conviction that our company was founded in 2016 by senior executives from the pharmaceutical and pharmacy industry. Since our inception, we have experienced rapid growth, surpassing 40 million EUR in sales in 2022. Our operations nowadays span across Northern Europe, with offices in Stockholm, Helsinki, and Munich, having a focus on five therapy areas: women’s health, urology, dermatology, allergy and general OTC. Currently, our portfolio comprises more than 30 products, a combination of our own as well as licensed pharmaceuticals from international companies such as Cosette, Perrigo, Dr. Pfleger, and Menarini. Nevertheless, a greater share of sales comes from our own products.